🇺🇸 FDA

Intelligence · Clinical Pipeline

R&D Pipeline Programs

ClinicalTrials.gov programs linked to pharma sponsors — phase, modality, and trial IDs for BD and competitive intelligence.

Programs indexed
20,548
Companies
1,769
Drugs tracked
4,797

Quick answer

NovaPharmaNews tracks 20,548 pharmaceutical R&D pipeline programs sourced from ClinicalTrials.gov, linked to sponsor companies. Each profile includes development phase, modality, trial status, NCT identifiers, and indication text — searchable for business development and competitive intelligence.

7,387 results for “Le” Clear

  1. Estradiol valerate, Dienogest (Natazia, Qlaira, BAY86-5027)

    Bayer HealthCare AG

    Primary Dysmenorrhea

    phase 3 small molecule completed

    1 trial

  2. EstroTep 500 MBq/mL, solution injectable

    The George Institute

    Women with ER+ HER2- metastatic breast cancer who progressed on first line therapy with CDK4/6 inhibitor and aromatase inhibitor

    phase 3 small molecule active

    1 trial

  3. Etavopivat A 100 mg, Etavopivat placebo., Etavopivat A 200 mg

    NovoThirteen

    sickle cell disease (SCD)

    phase 3 small molecule active

    1 trial

  4. Etavopivat A 200 mg

    NovoThirteen

    Sickle Cell Disease and Thalassaemia

    phase 3 small molecule active

    1 trial

  5. Etoposide

    The First People's Hospital of Lianyungang

    Non-Hodgkin's Lymphoma

    phase 3 small molecule active

    1 trial

  6. Etoposide

    The First People's Hospital of Lianyungang

    Multiple Myeloma

    phase 3 small molecule active

    1 trial

  7. Etripamil

    Milestone Pharmaceuticals

    Paroxysmal Supraventricular Tachycardia

    phase 3 small molecule terminated

    1 trial

  8. Etripamil NS

    Milestone Pharmaceuticals

    Paroxysmal Supraventricular Tachycardia

    phase 3 small molecule active

    2 trials

  9. Etripamil NS 70 mg

    Milestone Pharmaceuticals

    Tachycardia, Supraventricular

    phase 3 small molecule completed

    1 trial

  10. Etripamil NS 70 mg

    Milestone Pharmaceuticals

    Paroxysmal Supraventricular Tachycardia

    phase 3 small molecule completed

    2 trials

  11. Everolimus-ratiopharm® 2,5 mg Tabletten, GOSERELIN , ORSERDU 86 mg film-coated tablets, ORSERDU 345 mg film-coated tablets, LEUPRORELIN , DEXAMETHASONE , The investigational product is as follows: white tablets, elongated, flat, rounded edges, about 10 mm long and 4 mm wide, with the embossing "EV" on one side and "2.5" on the other side. The list of excipients of Placebo tablet is as follows: Lactose monohydrate, Polyplasdone, Cellulose microcrystalline, Magnesium stearate, Hypromellose., TRIPTORELIN

    Stemline Therapeutics B.V.

    patients with estrogen receptor-positive/human epidermal growth factor receptor 2-negative, ESR1-mutated, advanced breast cancer progressing to endocrine therapy and CDK4/6 inhibitors.

    phase 3 small molecule active

    1 trial

  12. Evinacumab

    Ultragenyx UK Limited

    Homozygous Familial Hypercholesterolemia

    phase 3 small molecule completed

    1 trial

  13. Evolocumab

    COLLEGIUM PHARMACEUTICAL, INC

    Sars-CoV-2 Infection

    phase 3 small molecule completed

    1 trial

  14. Evolocumab

    Amgen

    Severe Familial Hypercholesterolemia

    phase 3 mab completed

    1 trial

  15. Exa-cel

    Vertex Pharmaceuticals (Australia) Pty.

    Sickle Cell Disease

    phase 3 mab terminated

    1 trial

  16. Exoskeletal assisted walking

    United Therapeutics Europe Ltd

    Spinal Cord Injuries

    phase 3 other active

    1 trial

  17. Expanded autologous adipose-derived adult stem cells (eASCs)

    Takeda

    Complex Perianal Fistula

    phase 3 small molecule terminated

    1 trial

  18. Exparel Injectable Product

    Pacira Ireland Limited

    Coronary Artery Disease

    phase 3 small molecule completed

    1 trial

  19. Extended Release Buprenorphine

    BRIGHT MINDS BIOSCIENCES INC.

    Substance Use Disorder

    phase 3 small molecule completed

    1 trial

  20. Extended Release Naltrexone

    BRIGHT MINDS BIOSCIENCES INC.

    Opioid Use Disorder

    phase 3 small molecule completed

    1 trial

  21. Extended-release Guanfacine HCl (Intuniv, SPD503)

    Takeda

    Attention Deficit Hyperactivity Disorder (ADHD)

    phase 3 small molecule completed

    1 trial

  22. Extended-release Guanfacine Hydrochloride

    Takeda

    Attention-deficit/Hyperactivity Disorder

    phase 3 small molecule completed

    3 trials

  23. Extensively Hydrolyzed formula

    United Therapeutics Europe Ltd

    Cow Milk Allergy

    phase 3 other completed

    1 trial

  24. Eylea (Aflibercept, BAY86-5321)

    Regeneron UK Limited

    Retinopathy of Prematurity (ROP)

    phase 3 small molecule completed

    2 trials

Frequently asked questions

What is the NovaPharmaNews pipeline directory?

It is a searchable index of 20,548 clinical development programs grouped by sponsor company, with phase (Phase 1–3), modality, trial status, and linked NCT IDs from ClinicalTrials.gov.

Where does pipeline data come from?

Program records are derived from ClinicalTrials.gov and linked to NovaPharmaNews company profiles. Trial status and phase reflect registry data at last sync — verify on ClinicalTrials.gov before investment or partnering decisions. See our data sources page for attribution.

How do I find pipeline programs by company or phase?

Use the search box to match program name, indication, company name, or slug. Results are ordered with late-stage (Phase 3) programs first. Open any row to view the full program profile under its sponsor company.

Data attribution and licensing: Data sources